This maker of CPAP machines can gain market share as rival deals with a recall, Mizuho says

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Mizuho initiated coverage of the company with a buy rating and a price target of $255 per share, implying upside of 12.6% from Thursday's close.

An ongoing product recall for one of ResMed's top competitors opens up a big opportunity for the continuous positive airway pressure equipment maker, according to Mizuho. Analyst Anthony Petrone initiated coverage of the company with a buy rating and a price target of $255 per share, implying upside of 12.6% from Thursday's close.

"In aggregate, we see RMD settling at nearly ~60% permanent sleep device share, up from ~50%, as a result of the extended Philips CPAP recall," Petrone wrote on Thursday. Petrone added that ResMed has maintained its market share from a decline in Philips for longer than expected. "Our market model sized the US total market at $3.5bn today with a path to $6bn over the next 3-4 years," he said.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Here’s an idea: loose some weight so you don’t need it,

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 12. in BR

Brasil Últimas Notícias, Brasil Manchetes